ICON Public (ICLR) to Release Quarterly Earnings on Wednesday

ICON Public (NASDAQ:ICLR) will be announcing its earnings results after the market closes on Wednesday, April 24th. Analysts expect the company to announce earnings of $3.30 per share for the quarter. ICON Public has set its FY24 guidance at $14.50-$15.30 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.08 billion. On average, analysts expect ICON Public to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

ICON Public Price Performance

Shares of ICLR opened at $294.03 on Wednesday. ICON Public has a 1-year low of $181.92 and a 1-year high of $344.77. The stock has a market cap of $24.26 billion, a PE ratio of 39.84, a price-to-earnings-growth ratio of 1.45 and a beta of 1.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21. The firm has a fifty day moving average price of $315.94 and a 200 day moving average price of $280.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. LM Advisors LLC acquired a new stake in shares of ICON Public in the fourth quarter valued at approximately $26,000. First Horizon Advisors Inc. boosted its position in ICON Public by 10.9% during the first quarter. First Horizon Advisors Inc. now owns 551 shares of the medical research company’s stock worth $118,000 after acquiring an additional 54 shares during the last quarter. Alpha Paradigm Partners LLC acquired a new stake in ICON Public during the third quarter worth approximately $123,000. Crossmark Global Holdings Inc. acquired a new stake in ICON Public during the fourth quarter worth approximately $201,000. Finally, KB Financial Partners LLC boosted its position in ICON Public by 23.4% during the first quarter. KB Financial Partners LLC now owns 1,742 shares of the medical research company’s stock worth $424,000 after acquiring an additional 330 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ICLR. Robert W. Baird boosted their price target on shares of ICON Public from $345.00 to $362.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Truist Financial upped their target price on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. upped their target price on shares of ICON Public from $295.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Barclays upped their target price on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Finally, Mizuho reaffirmed a “buy” rating and issued a $346.00 target price on shares of ICON Public in a report on Thursday, April 4th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and an average target price of $319.45.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.